Form 4: Kineta Director and 10% Owner Shawn Iadonato Exercises Options and Adjusts Holdings Amidst TuHURA Biosciences Merger

Kineta, Inc. Director and 10% Owner Shawn Iadonato reported significant stock option exercises and related share transactions, increasing his direct beneficial ownership, in connection with the company's merger agreement with TuHURA Biosciences, Inc.

Summary

• Shawn Iadonato, a Director and 10% Owner of Kineta, Inc. (KANT), reported transactions on June 23, 2025, related to his beneficial ownership.
• He acquired 12,500 shares of Common Stock through the exercise of stock options at a price of $0.611 per share.
• He also acquired an additional 225,000 shares of Common Stock through the exercise of stock options at a price of $0.36 per share.
• Following these acquisitions, his direct beneficial ownership of Common Stock increased to 912,730 shares.
• Concurrently, he disposed of 52,353 shares of Common Stock at $0.26 per share, likely for tax withholding purposes related to the option exercises, resulting in a direct beneficial ownership of 860,377 shares after this disposition.
• An additional 8,553 shares are beneficially owned indirectly through an IRA.
• The stock options, granted under the 2022 Equity Incentive Plan, became fully vested on June 23, 2025, pursuant to an Optionholder Treatment Agreement and the Agreement and Plan of Merger with TuHURA Biosciences, Inc., which was approved by Kineta's stockholders on the same date.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While there's a disposition of shares, it's for tax purposes related to option exercises, which themselves represent an increase in direct beneficial ownership by a key insider (Director and 10% Owner). The transactions are also linked to the successful approval of a significant corporate merger, indicating strategic progress.

Positives

• A Director and 10% Owner, Shawn Iadonato, increased his direct beneficial ownership of Kineta Common Stock through option exercises, indicating continued confidence.
• The vesting of stock options and subsequent exercises are tied to the successful approval of the merger agreement with TuHURA Biosciences, Inc. by Kineta's stockholders, signaling progress on a strategic corporate event.

Negatives

• A portion of the acquired shares (52,353 shares) was disposed of at $0.26 per share, likely to cover tax obligations, which represents a sale of company stock by an insider.

Future Outlook

The document primarily reports past transactions and does not provide explicit forward-looking statements or guidance beyond the implication of the completed merger approval.

Industry Context

This filing reflects an insider transaction within the biotechnology or pharmaceutical industry, specifically for Kineta, Inc., a company undergoing a significant corporate restructuring through a merger with TuHURA Biosciences, Inc. The transactions are a direct consequence of the merger agreement and related option treatment.

Corporate Governance

Related Party Transactions

• The Optionholder Treatment Agreement, dated June 16, 2025, was entered into between Kineta, Inc. and the Reporting Person (Shawn Iadonato), who is a Director and 10% Owner, directly impacting his equity holdings and vesting schedule.

Stakeholder Impact

• Shareholders: The merger agreement was approved by stockholders, indicating their consent to the strategic direction and terms of the merger.
• Employees (specifically Shawn Iadonato as a Director): His equity compensation (stock options) vested as a result of the merger, impacting his personal financial stake in the company.

Next Steps

• The completion of the merger with TuHURA Biosciences, Inc. is implied by the stockholder approval on June 23, 2025, which was a condition for the option vesting.

Key Dates

Keywords

Kineta, KANT, Shawn Iadonato, Form 4, Insider Trading, Stock Options, Merger, TuHURA Biosciences, Equity Incentive Plan, Beneficial Ownership